(Q44518148)

3 December 2017

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia (English)

1 reference

3 December 2017

0 references

Robin A Emsley

1

1 reference

3 December 2017

Peter Buckley

series ordinal

2

1 reference

3 December 2017

A Martin Jones

series ordinal

3

1 reference

3 December 2017

Michael R Greenwood

series ordinal

4

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Journal of Psychopharmacology

3 December 2017

1 reference

3 December 2017

17

1 reference

3 December 2017

210-215

1 reference

3 December 2017

2

1 reference

Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression.

3 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

The frequency of associations between positive and negative symptoms and dysphoria in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

An investigation of the postpsychotic depressive syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

The many faces of Akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

'Akinetic Depression' in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

Mortality in current and former users of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002010

10.1177/0269881103017002010

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference